VolitionRx (VNRX) CSO uses 5,310 shares to cover tax bill

Rhea-AI Filing Summary

VolitionRx Ltd Chief Scientific Officer Jacob Vincent Micallef reported a tax-related share disposition rather than a market sale. On 2026-03-17, 5,310 shares of common stock at $0.19 per share were retained by VolitionRx and cancelled to satisfy his tax withholding obligations upon settlement of 11,800 restricted stock units. The filing states that no shares were sold by Micallef or VolitionRx in this transaction.

After this event, he holds 572,179 common shares directly. Indirectly, 55,000 shares are held by his spouse, and 38,113 shares are held by Borlaug Limited, where he serves as a controlling director with voting and dispositive control.

Insider Trade Summary

3 transactions reported

Mixed 3 txns

Insider Micallef Jacob Vincent

Role Chief Scientific Officer

Type	Security	Shares	Price	Value
Tax Withholding	Common Stock	5,310	$0.19	$1K
holding	Common Stock	--	--	--
holding	Common Stock	--	--	--

Holdings After Transaction: Common Stock — 572,179 shares (Direct); Common Stock — 55,000 shares (Indirect, By Spouse)

Footnotes (1)

1. Represents the aggregate number of shares of common stock retained by VolitionRx for cancellation to satisfy the tax withholding obligations of the reporting person upon settlement of 11,800 restricted stock units. No shares were sold by the reporting person or VolitionRx in such transaction. The shares of common stock are held directly by Borlaug Limited. The reporting person is a controlling director of Borlaug Limited and has voting and dispositive control over the shares of common stock held by Borlaug Limited.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Micallef Jacob Vincent

(Last) (First) (Middle)

1489 WEST WARM SPRINGS ROAD

SUITE 110

(Street)

HENDERSON NEVADA 89014

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
VOLITIONRX LTD [ VNRX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Scientific Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
03/17/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/17/2026		F		5,310(1)	D	$0.19	572,179	D
Common Stock								55,000	I	By Spouse
Common Stock								38,113	I	By Borlaug Limited(2)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents the aggregate number of shares of common stock retained by VolitionRx for cancellation to satisfy the tax withholding obligations of the reporting person upon settlement of 11,800 restricted stock units. No shares were sold by the reporting person or VolitionRx in such transaction.

2. The shares of common stock are held directly by Borlaug Limited. The reporting person is a controlling director of Borlaug Limited and has voting and dispositive control over the shares of common stock held by Borlaug Limited.

Remarks:

	/s/ Jacob Vincent Micallef	03/19/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did VolitionRx (VNRX) Chief Scientific Officer report in this Form 4?

The Chief Scientific Officer reported a tax-related share disposition, not an open-market trade. VolitionRx retained and cancelled 5,310 shares to cover his tax withholding on 11,800 vested restricted stock units, with no shares sold by him or the company.

Were any VolitionRx (VNRX) shares sold on the market in this filing?

No shares were sold on the market in this event. The 5,310 shares were retained by VolitionRx and cancelled to satisfy the officer’s tax withholding from restricted stock unit settlement, meaning there was no open-market buying or selling activity disclosed.

How many VolitionRx (VNRX) shares does the officer hold after the transaction?

Following the transaction, the officer directly holds 572,179 VolitionRx common shares. In addition, 55,000 shares are held indirectly by his spouse and 38,113 shares are held indirectly through Borlaug Limited, where he has voting and dispositive control over the shares.

What is the nature of the 5,310 VolitionRx (VNRX) shares reported in the Form 4?

The 5,310 shares represent stock retained and cancelled by VolitionRx to cover tax withholding. They relate to the settlement of 11,800 restricted stock units granted as equity compensation, and the filing notes this was a tax-withholding arrangement rather than a share sale.

How are indirect VolitionRx (VNRX) holdings structured for the reporting officer?

Indirect holdings include 55,000 shares held by the officer’s spouse and 38,113 shares held by Borlaug Limited. The filing explains he is a controlling director of Borlaug Limited and has voting and dispositive control over its VolitionRx common stock position.